Blueprint Medicines Corporation (BPMC): Business Model Canvas [Apr-2026 Updated]

You're looking at Blueprint Medicines Corporation (BPMC) post-Sanofi acquisition in July 2025, and honestly, the game has changed from pure discovery to focused execution. As an analyst who's seen this transition before, the focus is now squarely on driving AYVAKIT sales, which we project hitting between $700 million to $720 million this year, all while leveraging Sanofi's global muscle. This shift, supported by a solid $899.8 million cash position from Q1 2025, redefines their entire operating model. It's a classic pivot from biotech risk to commercial scale. To truly grasp how this subsidiary will generate revenue and manage its pipeline-from elenestinib to BLU-808-you need to see the full nine-block breakdown below.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Key Partnerships

You're looking at the structure of Blueprint Medicines Corporation's alliances as of late 2025, right after the company became part of Sanofi. This shift means the nature of several key relationships changed significantly mid-year.

Sanofi (Parent Company)

Following the acquisition completion on July 17 or 18, 2025, Sanofi is now the owner, providing the global commercial and financial infrastructure. The deal terms set the immediate financial framework:

• Upfront cash payment per share: $129.00.
• Total equity value at closing: Approximately $9.1 billion.
• Total potential equity value (including CVRs): Approximately $9.5 billion.

The integration is expected to be immediately accretive to gross margin for Sanofi, with accretion to business operating income and EPS projected after 2026. For context on the parent company's scale, Sanofi's Q1 2025 product sales from Dupixent alone were €3.48 billion.

CStone Pharmaceuticals

The collaboration for AYVAKIT commercialization in Greater China remains active, though under the new ownership structure. The original 2018 agreement involved Blueprint Medicines receiving an upfront cash payment of $40.0 million and eligibility for up to approximately $346.0 million in potential milestones. AYVAKIT is approved in China for GIST harboring the PDGFRA exon 18 mutation, and its inclusion in the NRDL (National Reimbursement Drug List) in China enhances its accessibility.

To further maximize commercial potential in mainland China, CStone entered an agreement with Jiangsu Hengrui Pharmaceuticals, granting them exclusive promotion rights for AYVAKIT. For this promotion service, CStone receives an upfront payment of RMB 35 million.

Contract Manufacturing Organizations (CMOs) and Specialty Pharmacy Networks

While specific contract values with CMOs like Catalent aren't public, the commercial supply chain is critical for the growing AYVAKIT franchise. The success of this network is reflected in the revenue guidance. Blueprint Medicines Corporation raised its global AYVAKIT net product revenue guidance for 2025 to $700 million to $720 million, on the path to achieving $2 billion in global AYVAKIT net product revenues by 2030. This product is currently approved and reimbursed in at least 16 countries overall.

The distribution relies on Specialty Pharmacy Networks in the U.S. to deliver this rare disease therapy. The estimated peak revenue opportunity for the entire Systemic Mastocytosis franchise, anchored by AYVAKIT, is now estimated at $4 billion.

Here's a quick look at the key financial anchors of the major product and corporate agreements:

Agreement/Metric	Financial/Statistical Figure	Context/Year
Sanofi Upfront Acquisition Price (per share)	$129.00	June 2025
Total Equity Value at Closing (Sanofi Deal)	Approx. $9.1 billion	July 2025
Potential CVR Milestone (BLU-808 Regulatory)	$4.00 per share	Contingent (Post-2025)
AYVAKIT Q1 2025 Net Product Revenue	$149.4 million	Q1 2025
AYVAKIT 2025 Net Revenue Guidance (Raised)	$700 - $720 million	2025 Fiscal Year
AYVAKIT Revenue Goal	$2 billion	By 2030
CStone Upfront Payment (Original Deal)	$40.0 million	2018 Agreement
CStone Promotion Rights Upfront Payment (Hengrui)	RMB 35 million	2024 Agreement

Contract Research Organizations (CROs)

CROs are essential for executing global clinical trials. Blueprint Medicines Corporation is actively driving enrollment in the HARBOR trial for elenestinib during 2025. Relying on these external groups means that if they miss deadlines or fail to meet obligations, the company could face repeating or extending trials, which significantly increases expenditures and delays commercialization.

• HARBOR trial site activation: 2025 target.
• Global AYVAKIT approvals: 16 countries (as of early 2025).
• Diagnosed SM patients in U.S. (CAGR over 5 years): 25 percent.

Finance: review CVR payment triggers against the Q3 2025 closing date by end of week.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Key Activities

You're looking at the core engine driving Blueprint Medicines Corporation's value creation as of late 2025. The Key Activities are centered on maximizing the current commercial success while aggressively advancing the next wave of precision therapies. Honestly, the execution here is what matters most for the near term.

Commercialization of AYVAKIT

The primary commercial activity is driving global sales for AYVAKIT (avapritinib). Blueprint Medicines is targeting global net product revenues for AYVAKIT to be in the range of $700 million to $720 million for the full year 2025. This guidance, which was raised from an earlier forecast of $680 million to $710 million, represents a 45 percent year-over-year growth at the midpoint.

You saw strong initial momentum, with Q1 2025 net product revenues from AYVAKIT hitting $149.4 million. That's a 61% jump compared to the $92.5 million seen in Q1 2024. The US market contributed $129.4 million in Q1 2025, while ex-US markets brought in $20 million. The company is working toward a long-term goal of achieving $2 billion in global AYVAKIT net product revenues by 2030. That's a solid plan for a durable franchise.

Research and Development (R&D)

Blueprint Medicines is heavily invested in advancing its pipeline, which is a critical activity for future revenue streams. They are focusing on key assets to build out their systemic mastocytosis (SM) franchise, which they project could reach a peak opportunity of $4 billion.

The R&D activities involve several crucial programs:

• Advance elenestinib (BLU-263) in the Phase 3 HARBOR trial for indolent systemic mastocytosis (ISM).
• Continue enrollment and site activation for the HARBOR trial of elenestinib.
• Advance BLU-808 through proof-of-concept (PoC) studies across various indications.
• Continue research programs for CDK2-targeted protein degraders.

Here's a quick look at the pipeline focus:

Asset	Status/Key Data Point	Target Indication Focus
Elenestinib	Phase 3 HARBOR trial underway	Systemic Mastocytosis (KIT D816V inhibitor)
BLU-808	PoC studies initiated; Phase 1 showed dose-dependent serum tryptase reductions exceeding 80 percent	Wild-type KIT inhibition for Allergic/Inflammatory Diseases

The Phase 1 data for BLU-808 showed a half-life of approximately 40 hours, supporting once-daily dosing.

Global Market Access

A key operational activity is securing the necessary payer coverage to ensure patients can actually get the medicine. Blueprint Medicines has a specific goal to achieve reimbursement for AYVAKYT in greater than or equal to 20 countries overall by the end of 2025.

To support this, the company continues to build out its commercial capabilities and infrastructure for marketing and market access in the U.S., Europe, and other regions. This involves collaboration with internal teams like Regulatory Affairs and external partners such as logistics providers and distributors to deliver treatment to "Every Patient, Every Time".

Precision Medicine Platform

The foundation of Blueprint Medicines Corporation's work is its research platform, which is dedicated to discovering and developing new targeted kinase inhibitors. This platform combines molecular targeting with world-class drug design capabilities, built on a deep understanding of kinase biology.

The core activity here is translating this scientific expertise into a broad pipeline, focusing on genetically defined patient populations. This approach is designed to offer improved efficacy with minimized off-target effects. The platform is also being used to develop other novel modalities, such as the aforementioned CDK-targeted therapies.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Key Resources

You're looking at the core assets that underpinned Blueprint Medicines Corporation's value proposition leading up to its acquisition by Sanofi in mid-2025. These resources are what made the company an attractive target, focusing heavily on proprietary science and a commercial asset.

Intellectual Property (IP): Patents protecting AYVAKIT and the KIT kinase inhibitor platform

The foundation of the value here is the exclusivity granted by intellectual property. Blueprint Medicines held a strong defensive moat around its lead asset and its underlying technology.

• AYVAKIT (avapritinib) is protected by 8 US drug patents filed between 2020 and 2025.
• The estimated generic launch date for AYVAKIT is Mar 08, 2042.
• The drug holds 7 exclusivities, with the last outstanding one set to expire in 2030.

This patent estate, covering the KIT kinase inhibitor platform, provided a long runway for revenue generation, which was a key factor in the acquisition valuation.

Approved Product: AYVAKIT (avapritinib) for systemic mastocytosis (SM) and GIST

AYVAKIT is the tangible, revenue-generating centerpiece of the Key Resources. Its performance in early 2025 demonstrated strong commercial traction in a rare disease setting.

Here's a look at the commercial performance leading up to the acquisition:

Metric	2024 Full Year	Q1 2025	2025 Guidance (Raised)	Long-Term Goal
Global Net Product Revenues	$479.0 million	$149.4 million	$700 - $720 million	$2 billion by 2030
US Net Product Revenues (Q1 2025)	N/A	$129.4 million	N/A	N/A
Ex-US Net Product Revenues (Q1 2025)	N/A	$20 million	N/A	N/A
Countries with Approval/Reimbursement	N/A	At least 16 countries	Aiming for $\geq$ 20 countries	N/A

AYVAKIT is approved for adults with advanced Systemic Mastocytosis (SM), including ASM, SM-AHN and MCL, and adults with unresectable or metastatic Gastrointestinal Stromal Tumors (GIST) harboring a PDGFRA exon 18 mutation. It is the first and only FDA-approved treatment for both advanced and indolent forms of SM.

Specialized Personnel: Expertise in precision oncology, rare disease commercialization, and immunology

The human capital was critical, representing the established infrastructure to discover, develop, and commercialize precision therapies. This expertise was what Sanofi sought to integrate into its growing immunology franchise.

• The company focused its scientific knowledge across two core areas: allergy/inflammation and oncology/hematology.
• Blueprint Medicines had approximately ~650 employees as of June 2025, with the majority based in the US.
• The team demonstrated proven commercial capability, successfully executing a rare disease launch.

This specialized team was key to advancing pipeline assets like elenestinib and BLU-808, which leverage the company's deep understanding of mast cell biology.

Financial Capital: Access to Sanofi's resources post-acquisition, plus $899.8 million in cash as of Q1 2025

Before the finalization of the merger, Blueprint Medicines maintained a strong balance sheet, which provided operational independence while pursuing pipeline advancement.

The financial position as of the end of the first quarter of 2025 was solid:

Cash, cash equivalents, and investments stood at $899.8 million on March 31, 2025. This was an increase from the $863.9 million held at the end of 2024. The company expected this position, combined with anticipated product revenues, to provide sufficient capital to achieve a self-sustainable financial profile, anticipating a year-over-year reduction in cash burn for 2025.

The acquisition itself was a massive capital event, with Sanofi paying an upfront cash consideration of $129.00 per share, representing an equity value of approximately $9.1 billion. The total transaction value, including contingent value rights (CVRs), was up to $9.5 billion.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Value Propositions

You're looking at the core reasons why prescribers and patients choose Blueprint Medicines Corporation (BPMC)'s therapies right now, late in 2025. It's all about precision targeting and the resulting patient benefit.

Targeted Therapy for SM: AYVAKIT, the only approved medicine for the root cause of SM

AYVAKIT (avapritinib) is positioned as the only approved medicine that targets the root cause for a broad spectrum of Systemic Mastocytosis (SM) patients, covering both advanced SM (ASM, SM with an associated hematological neoplasm, and mast cell leukemia) and indolent SM (ISM). The commercial uptake reflects this unique position. Blueprint Medicines raised its full-year 2025 global AYVAKIT net product revenue guidance to $700 million to $720 million. This follows a strong first quarter of 2025, where AYVAKIT generated $149.4 million in net product revenue, a 61% increase year-over-year. The company projects the peak revenue opportunity for the entire SM franchise, anchored by AYVAKIT, to reach $4 billion, with an annual revenue target of $2 billion for AYVAKIT by 2030.

The adoption metrics show deep satisfaction among the treated population:

• Approximately 75% of ISM patients started on the 25 mg dose.
• More than 95% of AYVAKIT patients strongly agree they are satisfied with it for their SM treatment.

Pipeline Expansion: Next-generation SM therapy (elenestinib) and a wild-type KIT inhibitor (BLU-808) for allergic/inflammatory diseases

Blueprint Medicines Corporation is building on its SM foundation with next-generation candidates. Elenestinib [BLU-263], a next-generation KIT D816V inhibitor for ISM, has initiated its Phase 3 HARBOR registrational trial. The goal here is to clinically differentiate this therapy by moving beyond symptom control toward disease modification for ISM patients.

For broader mast cell diseases, BLU-808, an oral wild-type KIT inhibitor, has shown compelling early data supporting its potential in allergic and inflammatory conditions. In a Phase 1 healthy volunteer study, BLU-808 demonstrated:

Metric	Data Point
Serum Tryptase Reduction	Exceeding 80 percent (dose-dependent)
Half-life	Approximately 40 hours (supports once-daily dosing)
Safety Profile (MAD cohorts)	All treatment-emergent AEs were Grade 1; no serious AEs or dose modifications

The company has initiated multiple proof-of-concept trials for BLU-808 in diseases like allergic rhinoconjunctivitis and chronic urticaria.

Improved Patient Outcomes: Durable clinical efficacy and sustained safety profile for long-term treatment

For patients on AYVAKIT long-term, the value proposition extends to structural benefits. Three-year follow-up data from the PIONEER study in ISM showed that treated patients achieved improvements in bone health. Specifically, comparing data from 6 months to 2 years on AYVAKIT, patients showed improvements in bone mineral density across key areas, including the lumbar spine, femoral neck, and femur. This reinforces the drug's safety and efficacy profile for chronic use, which is critical for a rare disease population.

Precision Medicine Focus: Small molecule inhibitors targeting specific, validated disease drivers

The entire Blueprint Medicines Corporation strategy centers on small molecule inhibitors hitting specific, validated molecular targets. AYVAKIT targets the KIT D816V mutation, the driver in most SM cases. The pipeline follows this theme:

• BLU-808 is designed as a highly potent and selective oral inhibitor of wild-type KIT, allowing for a tunable treatment approach.
• The company is also advancing other precision programs, including CDK2 and CDK4 targeted protein degraders for breast cancer.

This focus allows for the development of therapies with a differentiated clinical profile, aiming to optimize the benefit-risk for chronic treatment across mast cell diseases. Finance: draft 13-week cash view by Friday.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Customer Relationships

Blueprint Medicines Corporation focuses its customer relationships on ensuring patient access, engaging specialists directly, disseminating clinical evidence, and partnering with advocacy organizations to serve patients with systemic mastocytosis (SM) and other rare diseases.

Dedicated Patient Support:

• Programs exist for co-pay assistance and free medicine for eligible U.S. patients.

High-Touch Specialist Engagement:

The commercial engine has driven significant adoption across relevant specialties. For instance, there has been a tenfold increase in allergists prescribing AYVAKIT since its SM approval. The strategy also includes expansion into dermatology and gastroenterology to reach more diagnosed SM patients.

Medical Affairs Outreach:

Blueprint Medicines Corporation actively disseminates long-term clinical data at major medical congresses to educate specialists. The scope of this outreach in 2025 included:

Congress/Event	Date (Approx.)	Data Presentation Count	Presentation Type Detail
AAAAI / WAO Joint Congress	February/March 2025	14 total presentations	2 oral presentations and 12 poster presentations
European Hematology Association (EHA2025)	June 2025	Data presented	Showcased long-term AYVAKIT data
European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025	June 2025	Data presented	Showcased long-term AYVAKIT data

Patient Advocacy Group Collaboration:

Blueprint Medicines Corporation maintains deep ties with the patient community, reflecting over a decade of collaboration with clinical experts and patient advocates to transform SM treatment. This partnership approach is used to drive disease awareness and trial participation. A concrete example of this collaboration is the partnership with The Mast Cell Disease Society to create a patient registry to characterize the burden of SM.

• Conducted two global patient- and HCP-reported outcomes studies: TouchStone (U.S.) and PRISM (Europe).
• Collaborated with Twist Out Cancer on an initiative highlighting personal stories of those impacted by SM.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Channels

You're looking at how Blueprint Medicines Corporation moves its specialized medicines, like AYVAKIT®/AYVAKYT® (avapritinib), from the lab to the patient, which is a critical part of their strategy for their Systemic Mastocytosis (SM) franchise. This involves a highly controlled, multi-pronged approach, especially since they are scaling up commercial operations while advancing a deep pipeline.

Direct Sales Force: Specialized teams targeting U.S. and European physicians

Blueprint Medicines Corporation operates a 'high-performing commercial engine' designed for an integrated approach from research through commercialization, focusing on the U.S. and Europe for AYVAKIT. The company anticipates seeing continued modest increases in Selling, General, and Administrative (SG&A) expenses as they increase investment in their 'sales and marketing efforts for AYVAKIT.' This direct engagement is key to capturing the growing SM market, which they estimate has a peak revenue opportunity of $4 billion.

The success of this channel is reflected in their revenue trajectory:

• Global net product revenues for AYVAKIT in 2024 reached $479.0 million.
• The company raised its 2025 global net product revenue guidance for AYVAKIT to a range of $700 million to $720 million as of May 1, 2025.
• For the first quarter of 2025, global net product revenues from AYVAKIT were $149.4 million.

Specialty Pharmacy/Distribution: Controlled, high-cost drug distribution to ensure patient access

For a high-cost, specialized therapy like AYVAKIT, distribution is not a simple drop-off; it requires a controlled network. Blueprint Medicines is actively managing this channel, as AYVAKIT is now approved and reimbursed for at least one indication in at least 16 countries. The distribution strategy for these complex drugs often relies on specialty pharmacies, which are noted to be the fastest-growing distribution channel in the broader oncology market, handling drugs that need careful storage and patient support programs. Manufacturers like Blueprint Medicines define their channel models as Open, Limited, or Exclusive dispensing networks to manage access.

Here's a look at the geographic breakdown of the Q1 2025 product revenue, showing the split between the primary U.S. market and ex-U.S. markets served through these distribution channels:

Geography	Q1 2025 AYVAKIT Net Product Revenue
U.S.	$129.4 million
Ex-U.S.	$20 million

Global Regulatory Filings: Secure approvals in new geographies (e.g., EU, China via CStone)

Blueprint Medicines Corporation is executing a global strategy, leveraging its commercial capability in Europe alongside the U.S. launch. A Senior Director on the team is specifically responsible for ensuring medicine availability in all countries where they have marketing authorization outside the U.S. and China, which can involve utilizing a paid Named Patient Program in the interim. The company has plans for additional country launches in indolent SM (ISM) beyond the initial approvals. The focus on global regulatory progress supports the long-term goal of achieving $2 billion in AYVAKIT revenue by 2030.

Clinical Trial Sites: Enroll patients for pipeline assets like elenestinib (HARBOR trial)

The channels extend to clinical trial sites to advance pipeline assets, such as elenestinib, a next-generation KIT D816V inhibitor. The Phase 2/3 HARBOR trial (NCT04910685) for elenestinib in Indolent Systemic Mastocytosis (ISM) is actively recruiting. This trial structure requires a network of specialized clinical sites to enroll the target population. The estimated enrollment for the HARBOR study is 534 participants, with the trial involving sites across 11 countries throughout Europe. The study started in November 2021, with an estimated Primary Completion date set for September 30, 2032.

Key operational details for this channel include:

• Trial ID: NCT04910685.
• Estimated Enrollment: 534 participants.
• Geographic Reach: Sites in at least 11 countries in Europe.
• Status (as of November 2025): Recruiting.

Finance: draft 13-week cash view by Friday.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Customer Segments

You're looking at the core groups Blueprint Medicines Corporation (BPMC) targets with its approved therapies, primarily AYVAKIT (avapritinib) for Systemic Mastocytosis (SM) and GIST. The focus here is on the real-world numbers defining these groups as of late 2025.

Systemic Mastocytosis (SM) Patients: Both advanced and indolent forms of the rare disease.

The patient segment is defined by the rarity and the specific disease subtype, which dictates treatment. Blueprint Medicines estimates the peak revenue opportunity for its entire SM franchise to be $4 billion. The United States represents the largest patient pool for SM treatment.

For context on the patient pool size, the age-adjusted incidence rate of SM in the United States, based on data through 2021, was reported at 0.1 per 100,000 individuals. Systemic Mastocytosis accounts for over 95% of all adult mastocytosis cases.

Key characteristics of this patient group include:

• Approximately 80-90% of adults with SM harbor the KIT D816V mutation.
• Advanced SM (AdvSM), which includes subtypes like Aggressive SM (ASM), SM-AHN, or MCL, represents 10-20% of adult cases.
• In the PATHFINDER trial for AdvSM patients receiving first-line AYVAKIT, the overall response rate (ORR) was 87%.
• In the PIONEER study for Indolent SM (ISM), 246 patients received some dose of AYVAKIT.

Oncologists/Hematologists and Allergists/Immunologists: Prescribe AYVAKIT for SM and GIST.

These are the primary prescribers, with the commercial engine built to reach both oncology/hematology and allergy/immunology specialists. The company has expanded its reach to capture growth in the indolent SM space, which involves more allergists/immunologists.

Data from the fourth quarter of 2024 indicated trends in prescriber behavior:

• New prescribing volume was split approximately 40/60% between academic versus community accounts.
• Approximately 70% of new SM starts were initiated on the 25 mg dose of AYVAKIT.
• The data is based on U.S. SP/HUB prescriptions, which represented about 70% of total AYVAKIT volume in the U.S. as of Q4 2024.

Global Payers/Governments: Negotiate reimbursement for high-cost rare disease therapy.

Payer access is critical for a high-cost specialty drug. Blueprint Medicines has achieved broad coverage, which is a key enabler for the projected revenue growth. The company anticipates achieving reimbursement for AYVAKYT in ≥ 20 countries overall in 2025.

The financial dynamics with payers are quantified as follows:

Metric	Value/Rate (as of late 2024/early 2025)
Commercial Plan Coverage	99%
Medicare Plan Coverage	99%
AYVAKIT List Price (WAC, Jan 2025)	$40,837 per all doses/package sizes
Commercial Patients Paying $0/Month (with support)	Approximately 90%
Co-Pay Assistance Annual Maximum Benefit	$25,000

For comparison, the company projected global AYVAKIT net product revenues for 2025 to be between $680 million to $710 million.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Cost Structure

You're looking at the cost side of Blueprint Medicines Corporation's business model, which is heavily weighted toward fueling the pipeline and supporting the commercial launch of AYVAKIT. The costs reflect a company in a high-growth, high-investment phase, even with the Sanofi acquisition changing the landscape in mid-2025.

High R&D Investment

Research and Development expenses are a major cost driver, funding the advancement of priority programs like elenestadem and BLU-808. This investment is designed to build out the pipeline beyond the current revenue driver.

• Q1 2025 R&D expenses totaled $91.9 million.
• This represented an increase from $88.2 million in Q1 2024.
• R&D costs for Q1 2025 included $12.1 million in stock-based compensation expenses.

Commercialization Costs

Costs associated with bringing AYVAKIT to market and supporting its use are reflected in the Selling, General and Administrative (SG&A) line. This area saw a notable year-over-year increase as the commercial engine scaled up.

Here's the quick math on the operating expenses for the first quarter of 2025:

Cost Category	Q1 2025 Amount (Millions USD)	Year-over-Year Change
Selling, General and Administrative (SG&A)	$95.8 million	Up 15%
R&D Expenses	$91.9 million	Up 4%

What this estimate hides is the specific breakdown between sales force expansion, marketing, and patient support programs, but the SG&A increase was explicitly tied to AYVAKIT commercialization activities. SG&A for the quarter included $16.9 million in stock-based compensation.

Manufacturing and Supply Chain

The cost to produce and deliver the product, Cost of Sales, remains relatively low compared to R&D and SG&A, which is typical for a specialized, high-value pharmaceutical product.

• Cost of Sales for Q1 2025 was $2.8 million.
• This was a decrease from $3.2 million reported in Q1 2024.
• The decrease was due to lower sales to a collaboration partner, partially offset by higher product sales volume.

General and Administrative

Corporate overhead falls under SG&A. While the prompt notes partial integration into Sanofi's structure, the reported Q1 2025 SG&A of $95.8 million captures the operational costs Blueprint Medicines was incurring to run the corporate functions supporting its commercial and R&D efforts. The company maintained a strong liquidity position to cover these costs, with cash, cash equivalents, and investments at $899.8 million as of March 31, 2025. Also, as of that date, total debt stood at approximately $387.75 million.

Finance: draft 13-week cash view by Friday.

Blueprint Medicines Corporation (BPMC) - Canvas Business Model: Revenue Streams

You're looking at how Blueprint Medicines Corporation (BPMC) brings in the money as of late 2025. It's heavily weighted toward their commercial product, but pipeline milestones and partnership structures are key components of the overall financial picture.

Net Product Sales

The primary engine for Blueprint Medicines Corporation revenue is the sale of its marketed product, AYVAKIT (avapritinib). Following strong execution, the company raised its full-year 2025 guidance for global AYVAKIT net product revenues to be between $700 million and $720 million. This is a clear step up from the $479.0 million in global net product revenues achieved in the full year 2024. Honestly, the momentum is visible quarter-over-quarter; Q1 2025 alone brought in $149.4 million in AYVAKIT net product revenues. That first quarter performance included $129.4 million from the US market and $20 million from ex-US markets. The company maintains a long-term aspiration for AYVAKIT to achieve $2 billion in annual revenue by 2030, anchoring what they see as a peak systemic mastocytosis franchise opportunity of $4 billion.

Here's a quick look at the recent performance supporting this stream:

Metric	Value (2025 Guidance/Q1 Actual)	Reference Period
Projected AYVAKIT Net Product Revenue	$700 million to $720 million	Full Year 2025 Guidance
AYVAKIT Net Product Revenue	$149.4 million	Q1 2025
AYVAKIT US Net Product Revenue	$129.4 million	Q1 2025
AYVAKIT Ex-US Net Product Revenue	$20 million	Q1 2025
AYVAKIT Net Product Revenue	$479.0 million	Full Year 2024

Collaboration Revenue

Blueprint Medicines Corporation generates revenue through agreements with partners for ex-U.S. rights to its assets. The CStone Pharmaceuticals agreement, for instance, grants them rights in Greater China for several assets, including AYVAKIT, in exchange for tiered percentage royalties on sales. While specific 2025 collaboration revenue figures are not as prominently highlighted as product sales post-guidance raise, the prior year gives us a benchmark. Full-year 2024 collaboration and license revenues totaled $29.9 million. To be fair, Q1 2025 total revenue of $149.4 million was entirely attributed to net product sales, suggesting collaboration revenue was either minimal or recognized differently in that quarter, though prior quarter data showed $3.6 million in collaboration revenue in Q1 2024.

Key elements of the partnership revenue structure include:

• Tiered percentage royalties on sales in Greater China from CStone Pharmaceuticals.
• Initial upfront payment from the CStone agreement was $40.0 million.
• Total potential milestone payments from the CStone agreement were up to $346 million.

Contingent Value Rights (CVRs)

This stream represents potential, non-guaranteed future payments tied to the success of pipeline assets, most notably following the mid-2025 acquisition by Sanofi. The deal structure included a non-tradeable Contingent Value Right (CVR) for Blueprint Medicines Corporation shareholders. This CVR is conditioned on achieving specific milestones for the BLU-808 asset, which is a major focus for expansion beyond systemic mastocytosis. The total potential value from these CVRs is up to $400 million, structured as two separate payments.

The CVR structure is quite specific:

• One potential payment of $2 per CVR conditioned on a clinical development milestone for BLU-808.
• A second potential payment of $4 per CVR conditioned on a regulatory milestone for BLU-808.

Separately, as part of a prior transaction, Blueprint Medicines Corporation recorded a one-time net gain of $50.0 million in Q1 2025 related to the sale of its IDRx, Inc. equity investment to GSK plc, with an anticipated total payment of $80 million noted by management.

License Revenue

Historically, license revenue has been part of the mix, often bundled with collaboration revenue. The $29.9 million recognized in 2024 included both collaboration and license revenue. While the focus has clearly shifted to product sales and the CVR upside from the Sanofi deal, the underlying royalty streams from out-licensed assets, like the CStone agreement, continue to represent a component of non-product income. Finance: draft 13-week cash view by Friday.